A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX003 Administered by Intravenous Infusion in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2016
At a glance
- Drugs PRX 003 (Primary)
- Indications Psoriasis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Prothena
- 09 Jun 2016 Results published in Prothena Corporation media release.
- 09 Jun 2016 Results from this study presented at The European League Against Rheumatism (EULAR) 17th Annual European Congress of Rheumatology, as per Prothena Corporation media release.
- 14 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History